Ferroptosis Pathway and Process in Cardiovascular Disease

doi:10.12114/j.issn.1007-9572.2021.01.301

Abstract

Abstract: Ferroptosis is a novel mode of cell death that is neither apoptotic nor necrotic and has characteristics that are distinct from other forms of regulated cell death，such as：iron dependency，redox balance dosorder mediated by glutathione and glutathione peroxidase 4，and lipid peroxidation. Recent studies have found that ferroptosis also plays an important role in cardiovascular disease. This paper reviews the research progress of ferroptosis pathway and its role in cardiovascular disease. It has been found that the molecular regulation of ferroptosis has made rapid progress，but the research on ferroptosis and heart disease has just started. To further explore the mechanism of ferroptosis and its role in cardiovascular disease can provide more scientific basis for targeting ferroptosis as the prevention and treatment of heart disease.

Key words: Ferroptosis, Cell death, Glutathione peroxidase 4, Cardiovascular disease

摘要： 铁死亡是一种既非凋亡又非坏死的新型细胞死亡方式，具有不同于其他形式的调节性细胞死亡的特征，例如：铁依赖、谷胱甘肽和谷胱甘肽过氧化物酶4介导的氧化还原平衡紊乱，以及脂质过氧化。近年来研究发现铁死亡也在心血管疾病中发挥重要作用。此文总结了铁死亡通路及其在心血管疾病中的研究进展，发现铁死亡的分子调控方面已取得迅速进展，但铁死亡与心血管疾病之间的研究刚起步。进一步探讨铁死亡的机制及其在心血管疾病中发挥的作用，可为靶向铁死亡作为心血管疾病防治策略提供更多的科学依据。

关键词: 铁死亡, 细胞死亡, 谷胱甘肽过氧化物酶4, 心血管疾病

LYU Mingming,ZHENG Zaiyong,ZHANG Yulong, et al. Ferroptosis Pathway and Process in Cardiovascular Disease　[J]. Chinese General Practice, 2021, 24(29): 3769-3773. DOI: 10.12114/j.issn.1007-9572.2021.01.301.
吕明明,郑在勇,张玉龙等. 铁死亡通路与心血管疾病的研究进展[J]. 中国全科医学, 2021, 24(29): 3769-3773. DOI: 10.12114/j.issn.1007-9572.2021.01.301.

References

［1］DIXON S J，LEMBERG K M，LAMPRECHT M R，et al. Ferroptosis：an iron-dependent form of nonapoptotic cell death［J］. Cell，2012，149（5）：1060-1072. DOI：10.1016/j.cell.2012.03.042.
［2］YANG W S，SRIRAMARATNAM R，WELSCH M E，et al. Regulation of ferroptotic cancer cell death by GPX4［J］. Cell，2014，156（1/2）：317-331. DOI：10.1016/j.cell.2013.12.010.
［3］KIM S E，ZHANG L，MA K，et al. Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth［J］. Nat Nanotechnol，2016，11（11）：977-985. DOI：10.1038/nnano.2016.164.
［4］ISHII T，WARABI E，MANN G E. Circadian control of BDNF-mediated Nrf2 activation in astrocytes protects dopaminergic neurons from ferroptosis［J］. Free Radic Biol Med，2019，133：169-178. DOI：10.1016/j.freeradbiomed.2018.09.002.
［5］ADEDOYIN O，BODDU R，TRAYLOR A，et al. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells［J］. Am J Physiol Ren Physiol，2018，314（5）：F702-714. DOI：10.1152/ajprenal.00044.2017.
［6］FANG X，WANG H，HAN D，et al. Ferroptosis as a target for protection against cardiomyopathy［J］. PNAS，2019，116（7）：2672-2680. DOI：10.1073/pnas.1821022116.
［7］FANG X X，CAI Z X，WANG H，et al. Loss of cardiac ferritin H facilitates cardiomyopathy via Slc7a11-mediated ferroptosis［J］. Circ Res，2020，127（4）：486-501. DOI：10.1161/CIRCRESAHA.120.316509.
［8］GAO M H，MONIAN P，QUADRI N，et al. Glutaminolysis and transferrin regulate ferroptosis［J］. Mol Cell，2015，59（2）：298-308. DOI：10.1016/j.molcel.2015.06.011.
［9］LI W J，FENG G S，GAUTHIER J M，et al. Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation［J］. J Clin Invest，2019，129（6）：2293-2304. DOI：10.1172/JCI126428.
［10］YANG W S，KIM K J，GASCHLER M M，et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis［J］. Proc Natl Acad Sci USA，2016，113（34）：E4966-4975. DOI：10.1073/pnas.1603244113.
［11］GANZ T. Systemic iron homeostasis［J］. Physiol Rev，2013，93（4）：1721-1741. DOI：10.1152/physrev.00008.2013.
［12］GOZZELINO R，SOARES M P. Coupling heme and iron metabolism via ferritin H chain［J］. Antioxid Redox Signal，2014，20（11）：1754-1769. DOI：10.1089/ars.2013.5666.
［13］GAO M H，MONIAN P，PAN Q H，et al. Ferroptosis is an autophagic cell death process［J］. Cell Res，2016，26（9）：1021-1032. DOI：10.1038/cr.2016.95.
［14］HOU W，XIE Y，SONG X，et al. Autophagy promotes ferroptosis by degradation of ferritin［J］. Autophagy，2016，12（8）：1425-1428. DOI：10.1080/15548627.2016.1187366.
［15］MANCIAS J D，WANG X，GYGI S P，et al. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy［J］. Nature，2014，509（7498）：105-109. DOI：10.1038/nature13148.
［16］BROWN C W，AMANTE J J，CHHOY P，et al. Prominin2 drives ferroptosis resistance by stimulating iron export［J］. Dev Cell，2019，51（5）：575-586.e4. DOI：10.1016/j.devcel.2019.10.007.
［17］MAINES M D. The heme oxygenase system：a regulator of second messenger gases［J］. Annu Rev Pharmacol Toxicol，1997，37：517-554. DOI：10.1146/annurev.pharmtox.37.1.517.
［18］MAGTANONG L，KO P J，DIXON S J. Emerging roles for lipids in non-apoptotic cell death［J］. Cell Death Differ，2016，23（7）：1099-1109. DOI：10.1038/cdd.2016.25.
［19］BRIDGES R，LUTGEN V，LOBNER D，et al. Thinking outside the cleft to understand synaptic activity：contribution of the cystine-glutamate antiporter （System xc-） to normal and pathological glutamatergic signaling［J］. Pharmacol Rev，2012，64（3）：780-802. DOI：10.1124/pr.110.003889.
［20］SHINTOKU R，TAKIGAWA Y，YAMADA K，et al. Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3［J］. Cancer Sci，2017，108（11）：2187-2194. DOI：10.1111/cas.13380.
［21］IMAI H，MATSUOKA M，KUMAGAI T，et al. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis［J］. Curr Top Microbiol Immunol，2017，403：143-170. DOI：10.1007/82_2016_508.
［22］KAGAN V E，MAO G W，QU F，et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis［J］. Nat Chem Biol，2017，13（1）：81-90. DOI：10.1038/nchembio.2238.
［23］KAPRALOV A A，YANG Q，DAR H H，et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death［J］. Nat Chem Biol，2020，16（3）：278-290. DOI：10.1038/s41589-019-0462-8.
［24］DOLL S，PRONETH B，TYURINA Y Y，et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition［J］. Nat Chem Biol，2017，13（1）：91-98. DOI：10.1038/nchembio.2239.
［25］BERSUKER K，HENDRICKS J M，LI Z P，et al. The CoQ oxidoreductase FSP1 Acts parallel to GPX4 to inhibit ferroptosis［J］. Nature，2019，575（7784）：688-692. DOI：10.1038/s41586-019-1705-2.
［26］LEE H，ZANDKARIMI F，ZHANG Y L，et al. Energy-stress-mediated AMPK activation inhibits ferroptosis［J］. Nat Cell Biol，2020，22（2）：225-234. DOI：10.1038/s41556-020-0461-8.
［27］MASALDAN S，CLATWORTHY S A S，GAMELL C，et al. Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis［J］. Redox Biol，2018，14：100-115. DOI：10.1016/j.redox.2017.08.015.
［28］DHARMALINGAM P，TALAKATTA G，MITRA J，et al.
Pervasive genomic damage in experimental intracerebral hemorrhage：therapeutic potential of a mechanistic-based carbon nanoparticle［J］. ACS Nano，2020，14（3）：2827-2846. DOI：10.1021/acsnano.9b05821.
［29］ASANO T，KOMATSU M，YAMAGUCHI-IWAI Y，et al. Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells［J］. Mol Cell Biol，2011，31（10）：2040-2052. DOI：10.1128/MCB.01437-10.
［30］胡盛寿，高润霖，刘力生，等. 《中国心血管病报告2018》概要［J］. 中国循环杂志，2019，34（3）：209-220. DOI：10.3969/j.issn.1000-3614.2019.03.001.
HU S S，GAO R L，LIU L S，et al. Summary of the 2018 report on cardiovascular diseases in China［J］. Chin Circ J，2019，34（3）：209-220. DOI：10.3969/j.issn.1000-3614.2019.03.001.
［31］MISHRA P K，ADAMEOVA A，HILL J A，et al. Guidelines for evaluating myocardial cell death［J］. Am J Physiol Heart Circ Physiol，2019，317（5）：H891-922. DOI：10.1152/ajpheart.00259.2019.
［32］BULLUCK H，ROSMINI S，ABDEL-GADIR A，et al. Residual myocardial iron following intramyocardial hemorrhage during the convalescent phase of reperfused ST-segment-elevation myocardial infarction and adverse left ventricular remodeling［J］. Circ Cardiovasc Imaging，2016，9（10）：e004940. DOI：10.1161/CIRCIMAGING.116.004940.
［33］CHAN W，TAYLOR A J，ELLIMS A H，et al. Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction［J］. Circ Cardiovasc Interv，2012，5（2）：270-278. DOI：10.1161/circinterventions.111.966226.
［34］PARK T J，PARK J H，LEE G S，et al. Quantitative proteomic analyses reveal that GPX4 downregulation during myocardial infarction contributes to ferroptosis in cardiomyocytes［J］. Cell Death Dis，2019，10（11）：835. DOI：10.1038/s41419-019-2061-8.
［35］BABA Y，HIGA J K，SHIMADA B K，et al. Protective effects of the mechanistic target of rapamycin against excess iron and ferroptosis in cardiomyocytes［J］. Am J Physiol Heart Circ Physiol，2018，314（3）：H659-668. DOI：10.1152/ajpheart.00452.2017.
［36］LI W，FENG G，GAUTHIER J M，et al. Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation［J］. J Clin Invest，2019，129（6）：2293-2304. DOI：10.1172/jci126428.
［37］CHEN X Q，XU S D，ZHAO C X，et al. Role of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure［J］. Biochem Biophys Res Commun，2019，516（1）：37-43. DOI：10.1016/j.bbrc.2019.06.015.
［38］ANAND I S，GUPTA P. Anemia and iron deficiency in heart failure：current concepts and emerging therapies［J］. Circulation，2018，138（1）：80-98. DOI：10.1161/CIRCULATIONAHA.118.030099.
［39］MAEDER M T，KHAMMY O，DOS REMEDIOS C，et al. Myocardial and systemic iron depletion in heart failure implications for Anemia accompanying heart failure［J］. J Am Coll Cardiol，2011，58（5）：474-480. DOI：10.1016/j.jacc.2011.01.059.
［40］中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018［J］. 中华心血管病杂志，2018，46（10）：760-789. DOI：10.3760/cma.j.issn.0253-3758.2018.10.004.
［41］SIONIS A，SIONIS G A，MANITO L N，et al. Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure［J］. Rev Esp Cardiol，2016，69（12）：1119-1125. DOI：10.1016/j.rec.2016.10.015.
［42］LIU B，ZHAO C X，LI H K，et al. Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis［J］. Biochem Biophys Res Commun，2018，497（1）：233-240. DOI：10.1016/j.bbrc.2018.02.061.

[1]	ZHANG Dongli, SHEN Chong, ZHANG Weichuan, CHEN Haibin, ZHAO Jianjun. Efficacy and Safety of Programmed Death-1/Programmed Death-1 Ligand Inhibitors in the Treatment of Renal Cell Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3815-3822.
[2]	PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703.
[3]	ZHOU Sijiang, NING Zong. Research Progress of Ferroptosis in Acute Lung Injury [J]. Chinese General Practice, 2023, 26(03): 367-371.
[4]	SONG Pingan, CHEN Xiaoliang, YAO Yuan, GAO Jin, YANG Yang, CUI Hongchun, ZHANG Yi. Efficacy and Safety of PD-1 Inhibitors Monotherapy for Elderly Patients with Advanced Non-small Cell Lung Cancer [J]. Chinese General Practice, 2023, 26(02): 241-247.
[5]	Jinfa XU, Wencan SONG, Zhongxian ZHENG, Yu BAO, Gaoyan HUA, Qing CAI, Weiwei SHI, Xiufang ZHANG, Jianhua ZHANG, Zhou TONG, Guoan XIA, Fei LIU, Lintao LIU, Kesheng XIAO. Efficacy of China-produced Camrelizumab with Apatinib for First-line Treatment in Middle and Advanced Stages of Primary Liver Cancer [J]. Chinese General Practice, 2022, 25(26): 3258-3262.
[6]	Like ZHANG, Lei MA, Fangyu SHI, Quanxiao XU. Expression of Programmed Death Ligand 1 and Density of CD₈⁺ Tumor-infiltrating T-lymphocytes in Gastric Cancer Tissues and Their Relationship with Clinicopathological Characteristics and Prognosis of Patients with Gastric Cancer [J]. Chinese General Practice, 2022, 25(18): 2262-2267.
[7]	YANG Leiyi, LIN Sang, XIE Qibing, YIN Geng. Current Status of PD-1/PD-L1 Anti-tumor Therapy and Exploration of the Mechanism of Immune-related Adverse Events [J]. Chinese General Practice, 2022, 25(11): 1393-1398.
[8]	ZHU Yue，SUN Gengyun. Common Causes of Poor Efficacy of Immune Checkpoint Inhibitors in Special Populations　 [J]. Chinese General Practice, 2019, 22(17): 2099-2105.